NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: "STSS" and "STSSW"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is pleased to invite investors to a webinar on June 18, 2024, at 4:15 p.m. ET.
The exclusive event, hosted by RedChip Companies, will feature Robert Hayes, CEO of Sharps Technology, who will share insight into the Company's recent Asset Purchase Agreement and accompanying five-year, $200 million syringe Sales Agreement with Nephron.
Upon closing the asset acquisition, anticipated within 45 days, Sharps Technology will immediately initiate the first phase of its manufacturing implementation plan, including a new strategic partnership. This phase involves finalizing facility upgrades to support the production of pharmaceutical-grade COC prefillable syringes across three advanced production lines. The first line is expected to be ready to ship qualified products by early Q2 2025, with all three lines operational by Q4 2025. Two subsequent phases, expected to be completed by October 2027, will occur within the current facility structure.
Additionally, a five-year, $200 million sales agreement with Nephron will see Sharps' next-generation copolymer prefillable syringes manufactured at the South Carolina plant and 10mL SoloGard polypropylene syringes from Hungary qualified for future purchases. Sharps is also exploring sales opportunities for copolymer prefillable syringes with ...